Please login to the form below
medicines value
This page shows the latest medicines value news and features for those working in and with pharma, biotech and healthcare.
Who's calling the shots in European healthcare?
Natsis believes this is a pointer to the future direction of medicines pricing and reimbursement in Europe. ... PME: How do Europe’s healthcare systems need to evolve? EFPIA:Our current system means the costs are borne in year one from the medicines
Latest news
-
NICE unveils long-awaited review of methodologies
This will include how it should deal with uncertainty around clinical and cost effectiveness data for new medicines at launch. ... This review is a critical opportunity to ensure NICE’s methods are fit for the future and suitable for assessing the
-
Unruffled by ‘outlier’ claims, Vertex CEO upbeat on Orkambi breakthrough
cost and value of the drug, which has a list price of £104, 000 ($136, 000) per patient per year. ... to capture the full value of specialist medicines for small populations.
-
Greater Manchester backs move to outcome-based payment
able to access new and innovative medicines as early as possible and delivering better value for money.”. ... Outcome-based pricing could help the NHS get better value from new medicines and help our members better understand how treatments are
-
Vertex an “extreme outlier” in pricing and behaviour, says NHS England
However, Vertex rejected this offer, saying it “fails to adequately reflect the value of our current and future medicines and the number of patients that will be treated with these medicines". ... Other pharmaceutical companies are working
-
NICE rejects Novartis migraine treatment Aimovig
Ahmad adds: “NICE does not consider impact of diseases on broader society when evaluating the cost-effectiveness of medicines. ... We believe this fails to capture the true value of medicines like Aimovig.
More from news
Approximately 2 fully matching, plus 126 partially matching documents found.
Latest Intelligence
-
Mapping the patient journey: eight ways to improve support programmes
In recent years, PSPs have proved instrumental in securing payer support and market access, with companies increasingly wrapping support services around their medicines to provide value beyond the pill. ... But they have to be built with that value in
-
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Reflecting back, the five-year anniversary of biosimilars in the US marks an occasion to celebrate the value these high-quality, more affordable medicines have added to health systems and patient ... and value of biosimilar medicines.
-
Eliminating pharmaceutical rebates, is this déjà vu?
of therapies, the ability of medications to offset other healthcare costs, and the value of innovative medicines.
-
Could formulary intelligence be your brand differentiator?
Abasaglar – a biosimilar to Lantus (diabetes), offering a money-saving value proposition for medicines management. ... Sirdupla – a branded generic to Seretide (asthma), offering good cost savings for medicines management.
-
Risks, reforms and rewards: the evolving Russian healthcare market
In contrast, the value of medicines bought by the commercial or private healthcare sector was 991bn roubles in 2018, up from 948bn the previous year. ... The Russian market is dominated by generic drugs. Only 14.4% of medicines sold in the country in
More from intelligence
Approximately 1 fully matching, plus 49 partially matching documents found.
Latest appointments
-
Redx poaches AstraZeneca senior executive
grow this company into a very excising and meaningful entity that has the potential to create both important new medicines for patients and generate significant value for shareholders.".
-
Sanofi appoints Dr Yong-Jun Liu as head of research
April. In his new role, Dr Liu will be responsible for all of the Paris-based pharmaceutical company's research and will be tasked with delivering innovative and high-value medicines.
-
ABPI Scotland appoints Sandra Auld as director
the access to and use of new and innovative medicines for Scottish patients. . ... The ABPI Scotland team is fully committed to working with all of our stakeholders to support a common understanding and appreciation of the life-saving and life-enhancing
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
CRYOPORT APPOINTS MIND+MATTER AS PART OF A GLOBAL BRAND DEVELOPMENT TENDER
Its capabilities provide a comprehensive temperature-controlled solution for high-value and/or irreplaceable regenerative medicines and biopharmaceuticals in a cryogenic or temperature-controlled state. ... They are the third largest healthcare
-
Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603
its state-of-the-art nanotechnology to develop high value medicines where a reduced dose and improved drug delivery is needed, to overcome existing efficacy, tolerability and safety profile concerns.
-
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Before rotating into this practice, I spent the first year of the scheme working with OPEN Value, Informatics &Evidence (OPEN VIE), completing a 6-month rotation in market access followed by ... Getting to experience two disciplines within OPEN VIE was a
-
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The inclusion of innovative medicines in the WHO EML is an important step to help patients gain access to effective treatments. ... According to the WHO, more than 150 countries use the EML to guide decisions about which medicines represent the best
-
NHS medicines optimisation milestone
by 2020/21 if the NHS embraces the use of best value biological medicines in a proactive, systematic and safe way’. ... needs to redefine its value proposition and move the focus away from direct medicines costs to demonstrating how savings can be made
More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
-
Account Management
-
Competitive Salary Offered
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Content Editor - Biotechnology
-
Salary TBC
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- AZ showcases data for next-generation PARP inhibitor AZD5305
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- GSK discontinues two feladilimab trials in head and neck cancer
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Pfizer/BioNTech say their COVID-19 vaccine can be stored at warmer temperatures
- FDA approves new self-injection administration for Xolair
- Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Alexion and NICE agree confidential discount for Ultomiris use on the NHS
- Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
- Merck & Co halts development of potential COVID-19 drug MK-7110
- Virtually, the same: Is it time to rethink congress strategy?
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...
Latest intelligence
- InSite Events™ National Pharma Meeting: A Customer Story
- How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
- Fear or encouragement, which is best to drive behaviour change?
- The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
- The unheard, unseen, and uncorrected effects of COVID-19
- The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...
Quick links
Infographics
